

**INTERLOCAL HEALTH BENEFITS COMMITTEE  
SPECIAL CALLED MEETING  
September 1, 2022, 10:00 am  
10001 Hwy 70, Lakeland, TN 38002**

**I. CALL TO ORDER:**

**II. ROLL CALL:**

**III. CONSENT AGENDA**

1. Appeal#1 Claim No. 220823779P
2. Appeal#2 Claim No. 221752792P
3. Appeal#3 Claim No. 222083273U
4. Appeal#4 Claim No. 222133133U
5. Appeal#5 Claim No. 222153203U

**IV. DISCUSSION/ACTION:**

1. Discuss using pharmacy as Distribution site

**V. ANNOUNCEMENTS:**

**VI. ADJOURNMENT:**

---



**Consultant's Report  
Special Called Meeting  
September 01, 2022**

**1. CONSENT AGENDA**

**(A) Appeal 1: Claim No. 222083273U**

This appeal is for denial of the ADHD drug Vyvanse which was excluded with the TruDataRx changes on 1/1/2022. TruDataRx reviewed the clinical documentation from the provider, which indicates that the member has only tried and failed one long-acting agent prior to starting Vyvanse. The member must try and fail two long-acting agents prior to approval of Vyvanse appeal. Based on this information TruDataRx recommends upholding the denial of this appeal.

Sherrill Morgan recommends that the denial be upheld.

**(B) Appeal 2: Claim No. 221752792P**

This appeal is for denial of the diabetes drug Ozempic which was excluded with the TruDataRx changes on 1/1/2022. TruDataRx reviewed the clinical documentation from the provider which provided the following information: the member has prediabetes with a current A1C of 6.1% and the member has not tried and failed 3 of the covered alternatives. TruDataRx recommends upholding the denial of this appeal.

Sherrill Morgan recommends that the denial be upheld.

**(C) Appeal 3: Claim No. 220823779P**

This appeal is for denial of the diabetes drug Ozempic which was excluded with the TruDataRx changes on 1/1/2022. A review of claims data indicates the member has not tried and failed 3 of the 4 covered alternatives. TruDataRx attempted to reach the provider for any additional clinical information, but the provider did not respond after 3 attempts.

Sherrill Morgan recommends that the denial be upheld.

**(D) Appeal 4: Claim No. 222133133U**

This appeal is for denial of the diabetes drug Ozempic which was excluded with the TruDataRx changes on 1/1/2022. A review of claims data indicates the member has not tried and failed 3 of the 4 covered alternatives. TruDataRx attempted to reach the provider for any additional clinical information, but the provider did not respond after 3 attempts.

Sherrill Morgan recommends that the denial be upheld.

**(E) Appeal 5: Claim No. 222153203U**

This appeal is for denial of the diabetes drug Rybelsus which was excluded with the TruDataRx changes on 1/1/2022. A review of the claims data indicates the member has not tried and failed a minimum of three of the covered options. TruDataRx attempted to reach the provider for any additional clinical information, but the provider did not respond after 3 attempts.

Sherrill Morgan recommends that the denial be upheld.

**2. ACTION/DISCUSSION**

(A) Appeal 1: Claim No. 220210610Q

This appeal is to request additional payment to Baptist Memorial Hospital for under payment made by MedBen. MedBen indicated the payment made to BMH was in accordance with the agreement with them and EAS, and appropriate based on the submitted claim.

(B) Placeholder for Walter/Mark's request